1. Home
  2. ECX vs CABA Comparison

ECX vs CABA Comparison

Compare ECX & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECARX Holdings Inc. Ordinary shares

ECX

ECARX Holdings Inc. Ordinary shares

HOLD

Current Price

$1.21

Market Cap

388.7M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.25

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECX
CABA
Founded
2017
2017
Country
United Kingdom
United States
Employees
1432
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
388.7M
319.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ECX
CABA
Price
$1.21
$3.25
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
1.4M
3.6M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$819.14
N/A
Revenue Next Year
$32.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$1.26
52 Week High
$2.70
$4.23

Technical Indicators

Market Signals
Indicator
ECX
CABA
Relative Strength Index (RSI) 55.68 41.79
Support Level $0.90 $3.12
Resistance Level $1.28 $3.48
Average True Range (ATR) 0.11 0.27
MACD 0.03 -0.05
Stochastic Oscillator 58.44 13.42

Price Performance

Historical Comparison
ECX
CABA

About ECX ECARX Holdings Inc. Ordinary shares

ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the Peoples Republic of China. The companies core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: